Spider-venom Peptides that Target the Human NaV1.7 channel: Potential Analgesics for the Treatment of Chronic Pain

被引：0
|
作者：
Klint, Julie [1 ]
Anangi, Raveendra [1 ]
Mobli, Mehdi [1 ]
Knapp, Oliver [2 ]
Adams, David J. [2 ]
King, Glenn F. [1 ]
机构：
[1] Univ Queensland, Inst Mol Biosci, Brisbane, Qld, Australia
[2] RMIT Univ, Hlth Innovat Res Inst, Melbourne, Vic, Australia
来源：
TOXICON | 2012年 / 60卷 / 02期
关键词：
spider-venom peptides; NaV1.7; therapeutics; analgesics; structure-function relationships; pharmacophore; drug development;
D O I：
10.1016/j.toxicon.2012.04.032
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
31
引用
收藏
页码：110 / 111
页数：2
相关论文
共 33 条
  • [1] Rational Engineering Defines a Molecular Switch That Is Essential for Activity of Spider-Venom Peptides against the Analgesics Target NaV1.7
    Klint, Julie K.
    Chin, Yanni K. -Y.
    Mobli, Mehdi
    [J]. MOLECULAR PHARMACOLOGY, 2015, 88 (06) : 1002 - 1010
  • [2] Computational design of peptides to target Nav1.7 channel with high potency and selectivity for the treatment of pain
    Nguyen, Phuong T.
    Nguyen, Hai M.
    Wagner, Karen M.
    Stewart, Robert
    Singh, Vikrant
    Thapa, Parashar
    Ton, Anh Tuan
    Kondo, Richard P.
    Ghetti, Andre
    Pennington, Michael W.
    Hammock, Bruce
    Griffith, Theanne N.
    Sack, Jon T.
    Wulff, Heike
    Yarov-Yarovoy, Vladimir
    [J]. BIOPHYSICAL JOURNAL, 2023, 122 (03) : 309A - 309A
  • [3] Computational design of peptides to target NaV1.7 channel with high potency and selectivity for the treatment of pain
    Nguyen, Phuong T.
    Nguyen, Hai M.
    Wagner, Karen M.
    Stewart, Robert G.
    Singh, Vikrant
    Thapa, Parashar
    Chen, Yi-Je
    Lillya, Mark W.
    Ton, Anh Tuan
    Kondo, Richard
    Ghetti, Andre
    Pennington, Michael W.
    Hammock, Bruce
    Griffith, Theanne N.
    Sack, Jon T.
    Wulff, Heike
    Yarov-Yarovoy, Vladimir
    [J]. ELIFE, 2022, 11
  • [4] Selective Targeting of Nav1.7 with Engineered Spider Venom-Based Peptides
    Neff, Robert A.
    Wickenden, Alan D.
    [J]. CHANNELS, 2021, 15 (01) : 179 - 193
  • [5] Nav1.7 inhibitors for the treatment of chronic pain
    McKerrall, Steven J.
    Sutherlin, Daniel P.
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2018, 28 (19) : 3141 - 3149
  • [6] Nav1.7 Inhibitors: Potential Effective Therapy for the Treatment of Chronic Pain
    Abdel-Magid, Ahmed F.
    [J]. ACS MEDICINAL CHEMISTRY LETTERS, 2015, 6 (09): : 956 - 957
  • [7] Fluorescent- and tagged-protoxin II peptides: potent markers of the Nav1.7 channel pain target
    Montnach, Jerome
    De Waard, Stephan
    Nicolas, Sebastien
    Burel, Sophie
    Osorio, Nancy
    Zoukimian, Claude
    Mantegazza, Massimo
    Boukaiba, Rachid
    Beroud, Remy
    Partiseti, Michel
    Delmas, Patrick
    Marionneau, Celine
    De Waard, Michel
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 2021, 178 (13) : 2632 - 2650
  • [8] Binding mechanisms of the tarantula venom ProTx-II to the human NaV1.7 channel
    Ngo, Khoa
    Mateos, Diego Lopez
    Han, Yanxiao
    Yarov-Yarovoy, Vladimir
    Vorobyov, Igor
    Clancy, Colleen E.
    [J]. BIOPHYSICAL JOURNAL, 2022, 121 (03) : 187A - 187A
  • [9] Mechanism of inhibition by chlorpromazine of the human pain threshold sodium channel, Nav1.7
    Lee, Su-Jin
    Kim, Dong-Hyun
    Hahn, Sang June
    Waxman, Stephen G.
    Choi, Jin-Sung
    [J]. NEUROSCIENCE LETTERS, 2017, 639 : 1 - 7
  • [10] The NaV1.7 Channel Subtype as an Antinociceptive Target for Spider Toxins in Adult Dorsal Root Ganglia Neurons
    Goncalves, Tania C.
    Benoit, Evelyne
    Partiseti, Michel
    Servent, Denis
    [J]. FRONTIERS IN PHARMACOLOGY, 2018, 9
1234